Colombel JF; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health, Gut, vol.61, pp.241-247, 2012. ,
,
Development of the Crohn's disease digestive damage score, the Lémann score, Inflamm Bowel Dis, vol.17, pp.1415-1422, 2011. ,
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease, Gastroenterology, vol.148, pp.52-63, 2015. ,
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, pp.1324-1338, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01191653
Peyrin-Biroulet L. Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre, Dig Liver Dis, vol.45, pp.569-572, 2013. ,
ACCEPT study group. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease, Inflamm Bowel Dis, vol.23, pp.1425-1433, 2017. ,
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis, vol.18, pp.2218-2224, 2012. ,
Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease, J Crohns Colitis, vol.9, pp.1113-1119, 2015. ,
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet, vol.390, pp.2779-2789, 2018. ,
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, vol.42, pp.377-381, 2009. ,
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial, Gut, vol.63, pp.88-95, 2014. ,
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I, Aliment Pharmacol Ther, vol.35, pp.568-576, 2012. ,
,
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease, Aliment Pharmacol Ther, vol.34, pp.911-922, 2011. ,
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease, Inflamm Bowel Dis, vol.21, pp.331-336, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01850492
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor ? agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year, Dig Liver Dis, vol.46, pp.974-979, 2014. ,
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF? blocking agents, Inflamm Bowel Dis, vol.18, pp.2011-2017, 2012. ,
Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease, United European Gastroenterol J, vol.2, pp.30-37, 2014. ,
, , vol.160, pp.1-925
, bpgoffice@wjgnet.com Help Desk